|
1
|
Stein PD and Matta F: Epidemiology and
incidence: The scope of the problem and risk factors for
development of venous thromboembolism. Crit Care Clin. 27:907–932.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stein PD, Matta F, Keyes DC and Willyerd
GL: Impact of vena cava filters on in-hospital case fatality rate
from pulmonary embolism. Am J Med. 125:478–484. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stein PD and Matta F: Thrombolytic therapy
in unstable patients with acute pulmonary embolism: Saves lives but
underused. Am J Med. 125:465–470. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stein PD and Matta F: Case fatality rate
with pulmonary embolectomy for acute pulmonary embolism. Am J Med.
125:471–477. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Agnelli G, Buller HR, Cohen A, Curto M,
Gallus AS, Johnson M, Porcari A, Raskob GE and Weitz JI: PLIFY-EXT
Investigators: Apixaban for extended treatment of venous
thromboembolism. N Engl J Med. 368:699–708. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schulman S, Kearon C, Kakkar AK, Schellong
S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P,
Goldhaber SZ, et al: Extended use of dabigatran, warfarin, or
placebo in venous thromboembolism. N Engl J Med. 368:709–718. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Holbrook A, Schulman S, Witt DM, Vandvik
PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M and
Guyatt GH: American College of Chest Physicians: Evidence-based
management of anticoagulant therapy: Antithrombotic therapy and
prevention of thrombosis, 9th ed: American college of chest
physicians evidence. Based Clin Pract Guidelines. 141:(Suppl 2).
e152S–e184S. 2012.
|
|
8
|
Keeling D, Baglin T, Tait C, Watson H,
Perry D, Baglin C, Kitchen S and Makris M: British Committee for
Standards in Haematology: Guidelines on oral anticoagulation with
warfarin-fourth edition. Br J Haematol. 154:311–324. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Navgren M, Forsblad J and Wieloch M:
Bleeding complications related to warfarin treatment: A descriptive
register study from the anticoagulation clinic at Helsingborg
hospital. J Thromb Thrombolysis. 38:98–104. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nelson WW, Choi JC, Vanderpoel J, Damaraju
CV, Wildgoose P, Fields LE and Schein JR: Impact of co-morbidities
and patient characteristics on international normalized ratio
control over time in patients with nonvalvular atrial fibrillation.
Am J Cardiol. 112:509–512. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gallego P, Roldán V, Marin F, Gálvez J,
Valdés M, Vicente V and Lip GY: SAMe-TT2R2 score, time in
therapeutic range, and outcomes in anticoagulated patients with
atrial fibrillation. Am J Med. 127:1083–1088. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Grzymala-Lubanski B, Labaf A, Englund E,
Svensson PJ and Själander A: Mechanical heart valve prosthesis and
warfarin-treatment quality and prognosis. Thromb Res. 133:795–798.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hylek EM: Vitamin K antagonists and time
in the therapeutic range: Implications, challenges and strategies
for improvement. J Thromb Thrombolysis. 35:333–335. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ageno W, Turpie AG, Steidl L, Ambrosini F,
Cattaneo R, Codari RL, Nardo B and Venco A: Comparison of a daily
fixed 2.5-mg warfarin dose with a 5-mg, international normalized
ratio adjusted, warfarin dose initially following heart valve
replacement. Am J Cardiol. 88:40–44. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schulman S, Beyth RJ, Kearon C and Levine
MN: American College of Chest Physicians: Hemorrhagic complications
of anticoagulant and thrombolytic treatment: American College of
Chest Physicians Evidence Based Clinical Practice Guidelines (8th
Edition). Chest. 133:(6 Suppl). S257–S298. 2008. View Article : Google Scholar
|
|
16
|
Kovacs MJ, Rodger M, Anderson DR, Morrow
B, Kells G, Kovacs J, Boyle E and Wells PS: Comparison of 10-mg and
5-mg warfarin initiation nomograms together with low molecular
weight heparin for outpatient treatment of acute venous
thromboembolism. A randomized, double-blind, controlled trial. Ann
Intern Med. 138:714–719. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Garcia P, Ruiz W and Munárriz C Loza:
Warfarin initiation nomograms for venous thromboembolism. Cochrane
Database Syst Rev. 29:CD0076992016.
|
|
18
|
Garcia P, Ruiz W and Loza Munarriz C:
Warfarin initiation nomograms for venous thromboembolism. Cochrane
Database Syst Rev. 10:CD0076992013.
|
|
19
|
Mahtani KR, Heneghan CJ, Nunan D, Bankhead
C, Keeling D, Ward AM, Harrison SE, Roberts NW, Hobbs FD and Perera
R: Optimal loading dose of warfarin for the initiation of oral
anticoagulation. Cochrane Database Syst Rev. 12:CD 008685. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Farahmand S, Saeedi M, Javadi HH Seyed and
Khashayar P: High doses of warfarin are more beneficial than its
low doses in patients with deep vein thrombosis. Am J Emerg Med.
29:1222–1226. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mahtani KR, Heneghan CJ, Nunan D, Bankhead
C, Keeling D, Ward AM, Harrison SE, Roberts NW, Hobbs FD and Perera
R: Optimal loading dose of warfarin for the initiation of oral
anticoagulation. Cochrane Database Syst Rev.
12:CD0086852012.PubMed/NCBI
|
|
22
|
Suwanawiboon B, Kongtim P, Chinthammitr Y,
Ruchutrakool T and Wanachiwanawin W: The efficacy of 3-mg warfarin
initiating dose in adult Thai patients, who required long-term
anticoagulant therapy. J Med Assoc Thai. 94:(Suppl 1). S225–S231.
2011.PubMed/NCBI
|
|
23
|
Hu DY and Sun YH: Chinese Expert Consensus
of warfarin anticoagulant therapy. Zhong Hua Nei Ke Za Zhi.
1:76–82. 2013.(In Chinese).
|
|
24
|
Wallace JL, Reaves AB, Tolley EA, Oliphant
CS, Hutchison L, Alabdan NA, Sands CW and Self TH: Comparison of
initial warfarin response in obese patients versus non-obese
patients. J Thromb Thrombolysis. 36:96–101. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mueller JA, Patel T, Halawa A, Dumitrascu
A and Dawson NL: Warfarin dosing and body mass index. Ann
Pharmacother. 48:584–588. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Roberts GW, Helboe T, Nielsen CB, Gallus
AS, Jensen I, Cosh DG and Eaton VS: Assessment of an age-adjusted
warfarin initiation protocol. Ann Pharmacother. 37:799–803. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jensen BP, Chin PK, Roberts RL and Begg
EJ: Influence of adult age on the total and free clearance and
protein binding of (R)-and (S)-warfarin. Br J Clin Pharmacol.
74:797–805. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Van Spall HG, Wallentin L, Yusuf S,
Eikelboom JW, Nieuwlaat R, Yang S, Kabali C, Reilly PA, Ezekowitz
MD and Connolly SJ: Variation in warfarin dose adjustment practice
is responsible for differences in the quality of anticoagulation
control between centers and countries: An analysis of patients
receiving warfarin in the randomized evaluation of long-term
anticoagulation therapy (RE-LY) trial. Circulation. 126:2309–2316.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Self TH, Reaves AB, Oliphant CS and Sands
C: Does heart failure exacerbation increase response to warfarin? A
critical review of the literature. Curr Med Res Opin. 22:2089–2094.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hylek EM, Regan S, Go AS, Hughes RA,
Singer DE and Skates SJ: Clinical predictors of prolonged delay in
return of the international normalized ratio to within the
therapeutic range after excessive anticoagulation with warfarin.
Ann Intern Med. 135:393–400. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Szabó B, Merkely B and Takács I: The role
of vitamin D in the development of cardiac failure. Orv Hetil.
150:1397–1402. 2009.(In Hungarian). View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Anderson GM and Hull E: The use of
dicumarol as an adjunct to the treatment of congestive heart
failure; results in a controlled series of 61 cases. South Med J.
41:365–371. 1948. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cotlove E and Vorzimer JJ: Serial
prothrombin estimations in cardiac patients; diagnostic and
therapeutic implications; use of dicumarol. Ann Intern Med.
24:648–665. 1946. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wishart JH and Chapman CB: Dicoumarol
therapy in congestive heart failure. N Engl J Med. 239:701–704.
1948. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nathisuwan S, Dilokthornsakul P,
Chaiyakunapruk N, Morarai T, Yodting T and Piriyachananusorn N:
Assessing evidence of interaction between smoking and warfarin: a
systematic review and meta-analysis. Chest. 139:1130–1139. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bachmann K, Shapiro R, Fulton R, Carroll
FT and Sullivan TJ: Smoking and warfarin disposition. Clin
Pharmacol Ther. 25:309–315. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim MJ, Nafziger AN, Kashuba AD,
Kirchheiner J, Bauer S, Gaedigk A and Bertino JS Jr: Effects of
fluvastatin and cigarette smoking on CYP2C9 activity measured using
the probe S-warfarin. Eur J Clin Pharmacol. 62:431–436. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jordan SD, Stone MD, Alexander E, Haley J
and McKee A: Patient case: Impact of smoking cessation on
international normalized ratio. J Pharm Pract. 27:470–473. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Colucci VJ and Knapp JF: Increase in
international normalized ratio associated with smoking cessation.
Ann Pharmacother. 35:385–386. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
McGriff-Lee NJ, Csako G, Chen T, Dang DK,
Rosenfeld KG, Cannon RO, Macklin LR and Wesley RA: Anticoagulation
working group: Search for predictors of nontherapeutic INR results
with warfarin therapy. Ann Pharmacother. 39:1996–2002. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Takikawa Y, Harada M, Wang T and Suzuki K:
Usefulness and accuracy of the international normalized ratio and
activity percent of prothrombin time in patients with liver
disease. Hepatol Res. 44:92–101. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Denas G, Marzot F, Offelli P, Stendardo A,
Cucchini U, Russo R, Nante G, Iliceto S and Pengo V: Effectiveness
and safety of a management protocol to correct over-anticoagulation
with oral vitamin K: A retrospective study of 1,043 cases. J Thromb
Thrombolysis. 27:340–347. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Abe M, Maruyama N, Suzuki H, Okada K and
Soma M: International normalized ratio decreases after hemodialysis
treatment in patients treated with warfarin. J Cardiovasc
Pharmacol. 60:502–507. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dreisbach AW, Japa S, Gebrekal AB, Mowry
SE, Lertora JJ, Kamath BL and Rettie AE: Cytochrome P4502C9
activity in end-stage renal disease. Clin Pharmacol Ther.
73:475–477. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Arnason B, Matthisson J and Madsen H: Can
acute renal insufficiency increase the effect of warfarin? Ugeskr
Laeger. 171:10122009.[(In Danish)]. PubMed/NCBI
|
|
46
|
Limdi NA, Limdi MA, Cavallari L, Anderson
AM, Crowley MR, Baird MF, Allon M and Beasley TM: Warfarin dosing
in patients with impaired kidney function. Am J Kidney Dis.
56:823–831. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sakaan SA, Hudson JQ, Oliphant CS, Tolley
EA, Cummings C, Alabdan NA and Self TH: Evaluation of warfarin dose
requirements in patients with chronic kidney disease and end-stage
renal disease. Pharmacotherapy. 34:695–702. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ageno W, Gallus AS, Wittkowsky A, Crowther
M, Hylek EM and Palareti G: American College of Chest Physicians:
Oral anticoagulant therapy: Antithrombotic therapy and prevention
of thrombosis, 9th edition, American College of Chest Physicians
Evidence-Based Clinical Practice Guidelines. Chest. 141:(2 Suppl).
e44S–88S. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Glasheen JJ, Fugit RV and Prochazka AV:
The risk of overanticoagulation with antibiotic use in outpatients
on stable warfarin regimens. J Gen Intern Med. 20:653–656. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lane MA, Zeringue A and McDonald JR:
Serious bleeding events due to warfarin and antibiotic
co-prescription in a cohort of veterans. Am J Med. 127:657–663.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Glasheen JJ, Fugit RV and Prochazka AV:
Effect of levofloxacin co-coadministration on the international
normalized ratios during warfarin therapy-a comment.
Pharmacotherapy. 23:1079–1080. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Yamreudeewong W, Lower DL, Kipatrick DM,
Enlow AM, Burrows MM and Greenwood MC: Effect of levofloxacin
coadministration on the international normalized ratios during
warfarin therapy. Pharmacotherapy. 23:333–338. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Clark NP, Delate T, Riggs CS, Witt DM,
Hylek EM, Garcia DA, Ageno W, Dentali F and Crowther MA:
Warfarin-Associated Research Projects and Other Endeavors
Consortium: Warfarin interactions with antibiotics in the
ambulatory care setting. JAMA Intern Med. 174:409–416. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lane MA, Zeringue A and McDonald JR:
Serious bleeding events due to warfarin and antibiotic
co-prescription in a cohort of veterans. Am J Med. 127:657–663.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Holbrook AM, Pereira JA, Labiris R,
McDonald H, Douketis JD, Crowther M and Wells PS: Systematic
overview of warfarin and its drug and food interactions. Arch
Intern Med. 165:1095–1106. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Berkovitch M, Segal-Socher I, Greenberg R,
Bulkowshtein M, Arnon J, Merlob P and Or-Noy A: First trimester
exposure to cefuroxime: A prospective cohort study. Br J Clin
Pharmacol. 50:161–165. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Schelleman H, Bilker WB, Brensinger CM,
Wan F, Yang YX and Hennessy S: Fibrate/statin initiation in
warfarin users and gastrointestinal bleeding risk. Am J Med.
123:151–157. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Hickmott H, Wynne H and Kamali F: The
effect of simvastatin co-medication on warfarin anticoagulation
response and dose requirements. Thromb Haemost. 89:949–950.
2003.PubMed/NCBI
|
|
59
|
Cosgriff SW, Diefenbach AF and Vogt W Jr:
Hypercoagulability of blood associated with ACTH and cortisone
therapy. Am J Med. 9:752–756. 1950. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Costedoat-Chalumcau N, Amoura Z, Aymard G,
Sevin O, Wechsler B, Cacoub P, Du LT, Diquet B, Ankri A and Piette
JC: Potentiation of vitamin K antagonists by high-dose intravenous
methylprednisolone. Ann Intern Med. 132:631–635. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kaufman M: Treatment of multiple sclerosis
with high-dose corticosteroids may prolong the prothrombin time to
dangerous levels in patients taking warfarin. Mult Scler.
3:248–249. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Brigden ML, Kay C, Le A, Graydon C and
McLeod B: Audit of the frequency and clinical response to excessive
oral anticoagulation in an out-patient population. Am J Hematol.
59:22–27. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Ge B, Zhang Z and Zuo Z: Updates on the
clinical evidenced herb-warfarin interactions. Evid Based
Complement Alternat Med. 2014:9573622014. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Milić N, Milosević N, Kon S Golocorbin,
Bozić T, Abenavoli L and Borrelli F: Warfarin interactions with
medicinal herbs. Nat Prod Commun. 9:1211–1216. 2014.PubMed/NCBI
|
